Eloxx Pharmaceuticals Inc (ELOX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$
Buy
$
$ (+%)
Prices updated at 17 May 2025, 21:15
| Prices minimum 15 mins delay
Prices in USD
Eloxx Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. It is focused on building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2021 | 2022 |
|---|---|---|
| - | - | |
| - | - | |
| -66m | -34m | |
| - | - | |
| -67m | -36m | |
| -65m | -33m | |
| Sales, General and administrative | 20m | 11m |
| Interest expenses | 1m | 2m |
| Provision for income taxes | - | - |
| Operating expenses | 66m | 34m |
| Income before taxes | -67m | -36m |
| Net income available to common shareholders | -67m | -36m |
| -38 | -16.65 | |
| Net interest income | -1m | -2m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -38 | -16.65 |
| Free cash flow per share | -20.4299 | -16.7148 |
| Book value/share | 15.2328 | -2.2997 |
| Debt equity ratio | 0.571837 | - |
Balance sheet
Year | 2021 | 2022 |
|---|---|---|
| Current assets | 43m | 20m |
| Current liabilities | 10m | 23m |
| Total capital | 34m | -2m |
| Total debt | 13m | 13m |
| Total equity | 22m | -11m |
| Total non current liabilities | - | - |
| Loans | 12m | 9m |
| Total assets | 45m | 21m |
| Total liabilities | - | - |
| Cash and cash equivalents | 42m | 19m |
| Common stock | 2m | 2m |
Cash flow
Year | 2021 | 2022 |
|---|---|---|
| Cash at beginning of period | 25m | 43m |
| Cash dividends paid | - | - |
| -35m | -32m | |
| Investments (gains) losses | 2m | -66,000 |
| 43m | 19m | |
| Net income | - | - |
| -35m | -32m | |
| -89,000 | -66,000 |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
